Aquestive Therapeutics is a pharmaceutical company that develops and commercializes products to address unmet medical needs worldwide. Its product portfolio includes Sympazan for the treatment of lennox-gastaut syndrome, Suboxone for opioid dependence, and Zuplenz for nausea caused by chemotherapy and post-operative recovery. The company also develops proprietary product candidates, including Libervant and Exservan for the treatment of seizures and amyotrophic lateral sclerosis, respectively.